The indications of direct oral anticoagulants (DOACs) have expanded over the past 15
years. DOACs are effective and safe oral anticoagulants associated with lower bleeding …

Abstract Background Direct oral anticoagulants (DOACs) have shown a positive benefit-risk
balance in both clinical trials and real-world data, but approximately 2% to 3.5% of patients …

Background Direct oral anticoagulants (DOACs) have expanded the armamentarium for
antithrombotic therapy. Although DOAC-related major bleeding was associated with …

New guideline recommendations prefer direct oral anticoagulants (DOACs) over warfarin in
DOAC-eligible patients with atrial fibrillation and patients with venous thromboembolism. As …

Direct oral anticoagulants (DOACs) such as apixaban, dabigatran, edoxaban, and
rivaroxaban are mainly used in the prevention of thromboembolic complications in patients …

Purpose Current knowledge on managing major bleeding events with available hemostatic
agents, including their combined use with potential reversal agents, in patients taking direct …

Direct oral anticoagulants (DOAC s) have quickly become attractive alternatives to the long‐
standing standard of care in anticoagulation, vitamin K antagonist. DOAC s are indicated for …

INTRODUCTION—The use of any anticoagulant is associated with an increased risk of
bleeding, and bleeding complications can be life-threatening. Management of bleeding in …

Abstract Background Direct oral anticoagulants (DOACs) are now standard of care for the
management of thromboembolic risk. A prevalent issue of concern is how to manage direct …

Utilization of direct oral anticoagulants (DOAC) have steadily increased since their approval
and are now recommended over warfarin for both stroke prevention in nonvalvular atrial …